Friday, 16 October 2026European Markets

TINC And CRCAM LOIRE HTE L. Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - tinc (tinc.br) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
tinc (tinc.br) €11.95 4.54% 6.13%
crcam loire hte l. (crlo.pa) €66.00 4.53% 4%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. tinc (tinc.br)

4.54% forward dividend yield and 6.13% return on equity

tinc comm. va is an investment firm specializing in investments in public and private infrastructure, real assets, and energy sector. tinc comm. va is based in antwerpen, belgium.

earnings per share

as for profitability, tinc has a trailing twelve months eps of €0.78.

pe ratio

tinc has a trailing twelve months price to earnings ratio of 15.32. meaning, the purchaser of the share is investing €15.32 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.13%.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on oct 24, 2022, the estimated forward annual dividend rate is 0.54 and the estimated forward annual dividend yield is 4.54%.

more news about tinc.

2. crcam loire hte l. (crlo.pa)

4.53% forward dividend yield and 4% return on equity

caisse régionale de crédit agricole mutuel loire haute-loire société coopérative provides various banking products and services to individuals, professionals, farmers, business, public community and social housing, and associations in france. it offers accounts and cards; real estate loans and consumer credit; operating cycle, and company equipment and real estate financing; trade and export financing; savings products, such as life insurance, real estate investments, stock exchanges and financial investment, and retirement saving solutions; car and two-wheeler, home, personal, leisure and daily life, borrower, professional premises, professional vehicle, health, employee, activity, agricultural buildings, agricultural equipment and activity, and other insurance products; collection and payment services; cash management, business creation financing, medium-term credit, and leasing products; and treasury services. the company is based in saint-étienne, france. caisse régionale de crédit agricole mutuel loire haute-loire société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam loire hte l. has a trailing twelve months eps of €10.5.

pe ratio

crcam loire hte l. has a trailing twelve months price to earnings ratio of 6.29. meaning, the purchaser of the share is investing €6.29 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4%.

more news about crcam loire hte l..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com